Dysexecutive Syndrome A Specific Pattern of Cognitive Impairment in Systemic Sclerosis PDF Print E-mail
Sunday, 07 July 2013 20:31
Systemic sclerosis (SSc), also called scleroderma, is a connective-tissue disorder characterized by obliterative microvascular lesions and diffuse interstitial fibrosis. SSc damages the small and medium-sized vessels serving the skin, joints (especially fingers and toes), and internal organs such as the lungs, gastrointestinal tract, kidneys, and heart. In most patients, neurological involvement is limited, and localized to the peripheral nervous system. Raynaud phenomenon (RP) is a prominent early vascular feature of SSc, affecting 90% of patients during their disease course and, in some, progressing
to severe ischemia.

Although the typical manifestation of neurological involvement in SSc is mononeuropathy or polyneuropathy, some imaging studies have reported cerebral hypoperfusion and acute cerebral vasculitis. Cognitive dysfunction is one of the important signs of neurological involvement in systemic lupus erythematosus, affecting up to 80% of patients. In most, the cognitive dysfunction is attributed to RP or antiphospholipid antibodies.

Although RP is a well-known feature of SSc, little is known about cognitive functioning in SSc. Limited data from small series suggest possible impairment. In our study, we aimed to evaluate cognitive functioning in patients with SSc who had no manifest sign of neurological involvement and to determine whether they showed a specific pattern of cognitive impairment that might be caused by cerebral hypoperfusion.

To continue reading the full study, please download from the link provided below.

 
More articles :

» The Impact Of Art On Wellbeing In Autoimmune Disease

An innovative Newcastle research project is measuring the impact of creating art on the symptoms and overall wellbeing of people living with an autoimmune illness.A team at the University of Newcastle, in conjunction with the at John Hunter...

» Pulsed High-Dose Corticosteroids Combined With Low-Dose Methotrexate in Severe Localized Scleroderma

Alexander Kreuter, MD; Thilo Gambichler, MD; Frank Breuckmann, MD; Sebastian Rotterdam, MD; Marcus Freitag, MD; Markus Stuecker, MD; Klaus Hoffmann, MD; Peter Altmeyer, MDArch Dermatol. 2005;141:847-852Objective: To evaluate the efficacy of pulsed...

» What's Your Scleroderma Action Plan?

Living with any serious disease or condition like Scleroderma, is without a doubt, difficult. It is not hard to understand either, that we often can lose sight of what is important, including our way. We may also fall into to a false sense of...

» Dr. Dinesh Khanna Named, "Doctor Of The Year"

The Scleroderma Foundation named Dinesh Khanna, M.D., M.Sc., its 2011 Doctor of the Year during this year's National Patient Education Conference held last month in San Francisco. The award recognizes a skilled physician or researcher for his or her...

» Our Donors

The Scleroderma Care Foundation wishes to express our appreciation and gratitude for the generosity and support extended to us, by all of our donors to date, and the list keeps on growing. Your contributions have all been incredibly helpful and...

» Greater Global Cooperation and Collaboration in Scleroderma Research Required

Greater global cooperation and collaboration among Scleroderma researchers and clinicians would be all that is required to fuel a drive toward important discoveries and optimize outcomes for patients with this chronic, progressive, and often...